Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q2 FY24 results · Jul–Sep 2023
Suven Life Sciences reported revenue from operations of ₹3.06 crore (down 30.2% from Q2 FY23) and net loss of ₹12.68 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.06 | 4.39 | −30.2% | 3.80 | −19.4% |
| Other income | 5.14 | 0.21 | 25x | 5.64 | −8.8% |
| Total income | 8.20 | 4.59 | +78.6% | 9.44 | −13.1% |
| Profit before tax | (12.68) | (23.18) | Loss narrowed | (24.09) | Loss narrowed |
| Net profit for the period | (12.68) | (23.18) | Loss narrowed | (24.09) | Loss narrowed |
| EPS, basic (₹) | (0.58) | (1.59) | not comparable | (1.10) | Loss narrowed |
| Net margin (%) | -414.4 | -528.5 | -634.4 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3.06 | 4.39 | −30.2% | 3.80 | −19.4% |
| Other income | 5.14 | 0.21 | 25x | 5.64 | −8.8% |
| Total income | 8.20 | 4.59 | +78.6% | 9.44 | −13.1% |
| Profit before tax | 2.75 | (8.93) | Turned profit | (2.87) | Turned profit |
| Net profit for the period | 2.75 | (8.93) | Turned profit | (2.87) | Turned profit |
| EPS, basic (₹) | 0.13 | 0.61 | not comparable | (0.13) | Turned profit |
| Net margin (%) | 90.0 | -203.6 | -75.6 |
Consolidated
- Filed with BSE
- 18 Nov 2023, 11:08 IST
- Board meeting
- 04 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 Nov 2023, 11:08 IST
- Board meeting
- 04 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE